Abstract
Adrenocortical carcinoma (ACC) is an exceedingly rare tumour associated with poor survival for which radical surgical excision remains the only potentially curative treatment. This chapter is based on data collected by the author during publication of a systematic review of this topic published in the British Journal of Surgery [1] and during work as a senior author of guidelines for perioperative care of ACC patients published through a collaboration between the European Society of Endocrine Surgeons (ESES) and the European Network for the Study of Adrenal Tumours (ENSAT) [2].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Mihai R. Diagnosis, treatment and outcome of adrenocortical cancer. Br J Surg. 2015;102(4):291–306.
Gaujoux S, et al. European Society of Endocrine Surgeons (ESES) and European Network for the Study of Adrenal Tumours (ENSAT) recommendations for the surgical management of adrenocortical carcinoma. Br J Surg. 2017;104(4):358–76.
Kutikov A, et al. Effects of increased cross-sectional imaging on the diagnosis and prognosis of adrenocortical carcinoma: analysis of the National Cancer Database. J Urol. 2011;186(3):805–10.
Kerkhofs TM, et al. Surgery for adrenocortical carcinoma in The Netherlands: analysis of the national cancer registry data. Eur J Endocrinol. 2013;169(1):83–9.
Fassnacht M, et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer. 2009;115(2):243–50.
Arlt W, et al. Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors. J Clin Endocrinol Metab. 2011;96(12):3775–84.
Zini L, Porpiglia F, Fassnacht M. Contemporary management of adrenocortical carcinoma. Eur Urol. 2011;60(5):1055–65.
Zhang HM, et al. CT features and quantification of the characteristics of adrenocortical carcinomas on unenhanced and contrast-enhanced studies. Clin Radiol. 2012;67(1):38–46.
Sturgeon C, et al. Risk assessment in 457 adrenal cortical carcinomas: how much does tumor size predict the likelihood of malignancy? J Am Coll Surg. 2006;202(3):423–30.
Abdel-Aziz TE, et al. Risk of adrenocortical carcinoma in adrenal tumours greater than 8 cm. World J Surg. 2015;39(5):1268–73.
Petersenn S, et al. Computed tomography criteria for discrimination of adrenal adenomas and adrenocortical carcinomas: analysis of the German ACC registry. Eur J Endocrinol. 2015;172(4):415–22.
Libe R, Fratticci A, Bertherat J. Adrenocortical cancer: pathophysiology and clinical management. Endocr Relat Cancer. 2007;14(1):13–28.
Ilias I, et al. The optimal imaging of adrenal tumours: a comparison of different methods. Endocr Relat Cancer. 2007;14(3):587–99.
Harrison B. The indeterminate adrenal mass. Langenbeck’s Arch Surg. 2012;397(2):147–54.
Gust L, et al. Preoperative 18F-FDG uptake is strongly correlated with malignancy, Weiss score, and molecular markers of aggressiveness in adrenal cortical tumors. World J Surg. 2012;36(6):1406–10.
Nunes ML, et al. 18F-FDG PET for the identification of adrenocortical carcinomas among indeterminate adrenal tumors at computed tomography scanning. World J Surg. 2010;34(7):1506–10.
Watanabe H, et al. Adrenal-to-liver SUV ratio is the best parameter for differentiation of adrenal metastases from adenomas using 18F-FDG PET/CT. Ann Nucl Med. 2013;27(7):648–53.
Tessonnier L, et al. (18)F-FDG uptake at initial staging of the adrenocortical cancers: a diagnostic tool but not of prognostic value. World J Surg. 2013;37(1):107–12.
Kreissl MC, et al. [(1)(2)(3)I]Iodometomidate imaging in adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98(7):2755–64.
Lughezzani G, et al. The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation. Eur J Cancer. 2010;46(4):713–9.
Waldmann J, et al. Clinical impact of TP53 alterations in adrenocortical carcinomas. Langenbeck's Arch Surg. 2012;397(2):209–16.
Herrmann LJ, et al. TP53 germline mutations in adult patients with adrenocortical carcinoma. J Clin Endocrinol Metab. 2012;97(3):E476–85.
Raymond VM, et al. Prevalence of germline TP53 mutations in a prospective series of unselected patients with adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98(1):E119–25.
Tran TB, et al. Surgical management of advanced adrenocortical carcinoma: a 21-year population-based analysis. Am Surg. 2013;79(10):1115–8.
Gaujoux S, Brennan MF. Recommendation for standardized surgical management of primary adrenocortical carcinoma. Surgery. 2012;152(1):123–32.
Lim JH, Auh YH. Anatomic relation between the bare area of the liver and the right perirenal space. AJR Am J Roentgenol. 1994;162(3):733–4.
Lim JH, Kim B, Auh YH. Continuation of gas from the right perirenal space into the bare area of the liver. J Comput Assist Tomogr. 1997;21(4):667–70.
Icard P, et al. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg. 2001;25(7):891–7.
Gaujoux S, et al. Resection of adrenocortical carcinoma liver metastasis: is it justified? Ann Surg Oncol. 2012;19(8):2643–51.
Bellantone R, et al. Role of reoperation in recurrence of adrenal cortical carcinoma: results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma. Surgery. 1997;122(6):1212–8.
Fiori C, Daffara F, Defrancia S. Does nephrectomy during adrenalectomy for adrenal cancer improve oncological results? Eur Urol. 2012;11(1):e1105.
Bilimoria KY, et al. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer. 2008;113(11):3130–6.
Fassnacht M, et al. Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. J Clin Endocrinol Metab. 2006;91(11):4501–4.
Erdogan I, et al. The role of surgery in the management of recurrent adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98(1):181–91.
Kendrick ML, et al. Adrenocortical carcinoma: surgical progress or status quo? Arch Surg. 2001;136(5):543–9.
Libe R, et al. Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study. Ann Oncol. 2015;26(10):2119–25.
Nilubol N, Patel D, Kebebew E. Does lymphadenectomy improve survival in patients with adrenocortical carcinoma? A population-based study. World J Surg. 2016;40(3):697–705.
Saade N, Sadler C, Goldfarb M. Impact of regional lymph node dissection on disease specific survival in adrenal cortical carcinoma. Horm Metab Res. 2015;47(11):820–5.
Soreide JA, Brabrand K, Thoresen SO. Adrenal cortical carcinoma in Norway, 1970–1984. World J Surg. 1992;16(4):663–7; discussion 668
King DR, Lack EE. Adrenal cortical carcinoma: a clinical and pathologic study of 49 cases. Cancer. 1979;44(1):239–44.
Harrison LE, Gaudin PB, Brennan MF. Pathologic features of prognostic significance for adrenocortical carcinoma after curative resection. Arch Surg. 1999;134(2):181–5.
Reibetanz J, et al. Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma. Ann Surg. 2012;255(2):363–9.
Chiche L, et al. Adrenocortical carcinoma extending into the inferior vena cava: presentation of a 15-patient series and review of the literature. Surgery. 2006;139(1):15–27.
Turbendian HK, et al. Adrenocortical carcinoma: the influence of large vessel extension. Surgery. 2010;148(6):1057–64; discussion 1064.
Mihai R, et al. Outcome of operation in patients with adrenocortical cancer invading the inferior vena cava--a European Society of Endocrine Surgeons (ESES) survey. Langenbeck’s Arch Surg. 2012;397(2):225–31.
Bednarski BK, et al. Borderline resectable adrenal cortical carcinoma: a potential role for preoperative chemotherapy. World J Surg. 2014;38(6):1318–27.
Flanigan RC, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345(23):1655–9.
Dy BM, et al. Operative intervention for recurrent adrenocortical cancer. Surgery. 2013;154(6):1292–9; discussion 1299
Jurowich C, et al. Is there a role for laparoscopic adrenalectomy in patients with suspected adrenocortical carcinoma? A critical appraisal of the literature. Horm Metab Res. 2013;45(2):130–6.
Carnaille B. Adrenocortical carcinoma: which surgical approach? Langenbeck's Arch Surg. 2012;397(2):195–9.
Else T, et al. Adrenocortical carcinoma. Endocr Rev. 2014;35(2):282–326.
Di Carlo I, et al. Liver resection for hepatic metastases from adrenocortical carcinoma. HPB (Oxford). 2006;8(2):106–9.
Ripley RT, et al. Liver resection and ablation for metastatic adrenocortical carcinoma. Ann Surg Oncol. 2011;18(7):1972–9.
op den Winkel J, et al. Metastatic adrenocortical carcinoma: results of 56 pulmonary metastasectomies in 24 patients. Ann Thorac Surg. 2011;92(6):1965–70.
Kemp CD, et al. Pulmonary resection for metastatic adrenocortical carcinoma: the National Cancer Institute experience. Ann Thorac Surg. 2011;92(4):1195–200.
Dy BM, et al. Surgical resection of synchronously metastatic adrenocortical cancer. Ann Surg Oncol. 2015;22(1):146–51.
Porpiglia F, et al. A debate on laparoscopic versus open adrenalectomy for adrenocortical carcinoma. Horm Cancer. 2011;2(6):372–7.
Aspinall SR, et al. How is adrenocortical cancer being managed in the UK? Ann R Coll Surg Engl. 2009;91(6):489–93.
Grubbs EG, et al. Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane. Ann Surg Oncol. 2010;17(1):263–70.
Hermsen IG, et al. Surgery in adrenocortical carcinoma: importance of national cooperation and centralized surgery. Surgery. 2012;152(1):50–6.
Ip JC, et al. Improving outcomes in adrenocortical cancer: an Australian perspective. Ann Surg Oncol. 2015;22(7):2309–16.
Bergamini C, et al. Complications in laparoscopic adrenalectomy: the value of experience. Surg Endosc. 2011;25(12):3845–51.
Park HS, Roman SA, Sosa JA. Outcomes from 3144 adrenalectomies in the United States: which matters more, surgeon volume or specialty? Arch Surg. 2009;144(11):1060–7.
Simhan J, et al. Trends in regionalization of adrenalectomy to higher volume surgical centers. J Urol. 2012;188(2):377–82.
Gallagher SF, et al. Trends in adrenalectomy rates, indications, and physician volume: a statewide analysis of 1816 adrenalectomies. Surgery. 2007;142(6):1011–21. discussion 1011-21
Saunders BD, et al. Trends in utilization of adrenalectomy in the United States: have indications changed? World J Surg. 2004;28(11):1169–75.
Lombardi CP, et al. Adrenocortical carcinoma: effect of hospital volume on patient outcome. Langenbeck’s Arch Surg. 2012;397(2):201–7.
Fassnacht M, et al. Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers. J Clin Endocrinol Metab. 2010;95(11):4925–32.
Gratian L, et al. Treatment patterns and outcomes for patients with adrenocortical carcinoma associated with hospital case volume in the United States. In: Ann Surg Oncol, vol. 21; 2014. p. 3509.
Greco F, et al. Laparoscopic adrenalectomy in urological centres—the experience of the German Laparoscopic Working Group. BJU Int. 2011;108(10):1646–51.
Margonis GA, et al. Outcomes after resection of cortisol-secreting adrenocortical carcinoma. Am J Surg. 2016;211(6):1106–13.
Margonis GA, et al. Adrenocortical carcinoma: impact of surgical margin status on long-term outcomes. Ann Surg Oncol. 2016;23(1):134–41.
Papotti M, et al. Pathology of the adrenal cortex: a reappraisal of the past 25 years focusing on adrenal cortical tumors. Endocr Pathol. 2014;25(1):35–48.
Beuschlein F, et al. Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection. J Clin Endocrinol Metab. 2015;100(3):841–9.
Zini L, et al. External validation of a nomogram predicting mortality in patients with adrenocortical carcinoma. BJU Int. 2009;104(11):1661–7.
Freire DS, et al. Development and internal validation of an adrenal cortical carcinoma prognostic score for predicting the risk of metastasis and local recurrence. Clin Endocrinol. 2013;79(4):468–75.
de Krijger RE, Bertherat J. 5th international ACC symposium: classification of adrenocortical cancers from pathology to integrated genomics: real advances or lost in translation? Horm Cancer. 2016;7(1):3–8.
Acknowledgement
Disclosure: The author declares no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Science+Business Media Singapore
About this chapter
Cite this chapter
Mihai, R. (2018). Surgery for Adrenocortical Cancer: Evidence-Based Recommendations. In: Parameswaran, R., Agarwal, A. (eds) Evidence-Based Endocrine Surgery. Springer, Singapore. https://doi.org/10.1007/978-981-10-1124-5_29
Download citation
DOI: https://doi.org/10.1007/978-981-10-1124-5_29
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-10-1123-8
Online ISBN: 978-981-10-1124-5
eBook Packages: MedicineMedicine (R0)